Pharmaceuticals & Healthcare

As pioneers with regards to the regulatory approval and use of biosimilars, the EU is now reaping the economic benefits, with increased patient access and healthcare system efficiencies generated through competition on the one hand and continued innovation on the other – an essential equilibrium for securing a sustainable future for the European biologics market.

However, the increasing focus on maximizing short-term savings and the high diversity of policies governing the daily practice of off-patent biologics may eventually undermine this goal.

It is imperative to ask: How should the policy ...

Pugatch Consilium is today releasing the sixth edition of the Building the Bioeconomy, a series of papers commissioned by the Biotechnology Industry Organization. Since 2013, the series has taken the pulse of biotechnology policies in the main economies worldwide, and has shown that policy choices are key determinants of success in growing biotechnology sectors.
This year’s edition adds to the analysis eleven countries, further increasing the geographic and economic diversity of the countries sampled. Yet, the findings of the report ...

Professor Meir Pugatch spoke last week at the forum “How to Accelerate Taiwan Biomedical Policy Momentum as an Asia-Pacific Biomedical R&D Hub” hosted by the International Research-based Pharmaceutical Manufacturers Association (IRPMA), and included the Vice President of Taiwan Chien-Jen Chen and Minister Ming-Hsin Kung from the Executive Yuan, as well as leading figures from Taiwan’s Government, academia and industry.

Professor Pugatch presented a comprehensive analysis of Taiwan’s competitiveness in the biotech sector, as well as recent improvements to, and remaining challenges in, Taiwan’s path to leadership in global ...

A Pugatch Consilium study released today commissioned by the Biotechnology Innovation Organization (BIO) highlights strategies, policies and best practices that have been successful in creating an environment in which biotechnology innovation can flourish around the world.

The fifth edition of the Building the Bioeconomy report shows the correlation between economies with pro-innovation policy frameworks and those achieving strong biotechnology outputs. By examining 28 different indicators ranging from public policy inputs to biotechnology outputs, the report provides a full and detailed ...

Professor Meir Pugatch spoke yesterday at the event: “Building a sustainable Policy Framework for Biologics and Biosimilar Medicines in Europe”, which took place at the European Parliament, and included members from the European Commission and organizations such as Medicines for Europe, ESMO and EPF. Professor Pugatch presented the findings of a new study by Pugatch Consilium, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

With 38 biosimilar medicines approved and marketed and hundreds of clinical trials on ...

Pugatch Consilium unveiled at the Financial Times Latin America Healthcare & Life Sciences Summit in Sao Paulo Brazil the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Latin America Special Report. This Report is derived from the main 2017 BCI Survey, a global executive opinion survey and index that measures the relative attractiveness of economies to investment from biopharmaceutical research-based companies.

The Report deep-dives into ten Latin American countries: Argentina, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Mexico, Panama and Peru. ...